 | • レポートコード：D0GIR-00974 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、二重特異性抗体療法の世界市場を広く調査・分析し、今後の市場展望をまとめております。二重特異性抗体療法の種類別市場規模（非対称抗体、対称抗体、フラグメント抗体）、用途別市場規模（大腸癌、前立腺癌、子宮頸癌、乳癌、肺癌、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Amgen Inc.、Aptevo Therapeutics Inc.、OncoMed Pharmaceuticals, Inc.、Roche、MacroGenics, Inc.、AbbVie Inc.、Regeneron Pharmaceuticals, Inc.、Xencor, Inc.、Glenmark Pharmaceuticals Limited、Ligand Pharmaceuticals, Inc.、Fresenius、Merus ・地域別グローバル市場分析 2015年-2020年 ・二重特異性抗体療法の北米市場（アメリカ、カナダ、メキシコ） ・二重特異性抗体療法のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・二重特異性抗体療法のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・二重特異性抗体療法の南米市場（ブラジル、アルゼンチン） ・二重特異性抗体療法の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：非対称抗体、対称抗体、フラグメント抗体 ・用途別分析：大腸癌、前立腺癌、子宮頸癌、乳癌、肺癌、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Bi-Specific Antibodies Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Bi-Specific Antibodies Therapy sales will be xx in 2020 from Bi-Specific Antibodies Therapy million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Bi-Specific Antibodies Therapy market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Bi-Specific Antibodies Therapy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Bi-Specific Antibodies Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Bi-Specific Antibodies Therapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Bi-Specific Antibodies Therapy market has been segmented into:
Asymmetric Antibodies
Symmetric Antibodies
Fragment Antibodies
By Application, Bi-Specific Antibodies Therapy has been segmented into:
Colon Cancer
Prostate Cancer
Cervical Cancer
Breast Cancer
Lung Cancer
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Bi-Specific Antibodies Therapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Bi-Specific Antibodies Therapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Bi-Specific Antibodies Therapy market.
The report offers in-depth assessment of the growth and other aspects of the Bi-Specific Antibodies Therapy market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Bi-Specific Antibodies Therapy Market Share Analysis
Bi-Specific Antibodies Therapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Bi-Specific Antibodies Therapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Bi-Specific Antibodies Therapy sales, revenue and market share for each player covered in this report.
The major players covered in Bi-Specific Antibodies Therapy are:
Amgen Inc.
Aptevo Therapeutics Inc.
OncoMed Pharmaceuticals, Inc.
Roche
MacroGenics, Inc.
AbbVie Inc.
Regeneron Pharmaceuticals, Inc.
Xencor, Inc.
Glenmark Pharmaceuticals Limited
Ligand Pharmaceuticals, Inc.
Fresenius
Merus
Among other players domestic and global, Bi-Specific Antibodies Therapy market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Bi-Specific Antibodies Therapy Market Overview
1.1 Product Overview and Scope of Bi-Specific Antibodies Therapy
1.2 Classification of Bi-Specific Antibodies Therapy by Type
1.2.1 Global Bi-Specific Antibodies Therapy Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Type in 2019
1.2.3 Asymmetric Antibodies
1.2.4 Symmetric Antibodies
1.2.5 Fragment Antibodies
1.3 Global Bi-Specific Antibodies Therapy Market by Application
1.3.1 Overview: Global Bi-Specific Antibodies Therapy Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Colon Cancer
1.3.3 Prostate Cancer
1.3.4 Cervical Cancer
1.3.5 Breast Cancer
1.3.6 Lung Cancer
1.3.7 Others
1.4 Global Bi-Specific Antibodies Therapy Market by Regions
1.4.1 Global Bi-Specific Antibodies Therapy Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Bi-Specific Antibodies Therapy (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Bi-Specific Antibodies Therapy Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Bi-Specific Antibodies Therapy Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Bi-Specific Antibodies Therapy Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Bi-Specific Antibodies Therapy Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Bi-Specific Antibodies Therapy Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Bi-Specific Antibodies Therapy Industry Impact
1.5.1 COVID-19 Potential Implications for the Bi-Specific Antibodies Therapy
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Bi-Specific Antibodies Therapy
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Amgen Inc. Details
2.1.2 Amgen Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Amgen Inc. SWOT Analysis
2.1.4 Amgen Inc. Product and Services
2.1.5 Amgen Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Aptevo Therapeutics Inc.
2.2.1 Aptevo Therapeutics Inc. Details
2.2.2 Aptevo Therapeutics Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Aptevo Therapeutics Inc. SWOT Analysis
2.2.4 Aptevo Therapeutics Inc. Product and Services
2.2.5 Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.3 OncoMed Pharmaceuticals, Inc.
2.3.1 OncoMed Pharmaceuticals, Inc. Details
2.3.2 OncoMed Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 OncoMed Pharmaceuticals, Inc. SWOT Analysis
2.3.4 OncoMed Pharmaceuticals, Inc. Product and Services
2.3.5 OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.5 MacroGenics, Inc.
2.5.1 MacroGenics, Inc. Details
2.5.2 MacroGenics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 MacroGenics, Inc. SWOT Analysis
2.5.4 MacroGenics, Inc. Product and Services
2.5.5 MacroGenics, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.6 AbbVie Inc.
2.6.1 AbbVie Inc. Details
2.6.2 AbbVie Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 AbbVie Inc. SWOT Analysis
2.6.4 AbbVie Inc. Product and Services
2.6.5 AbbVie Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Regeneron Pharmaceuticals, Inc.
2.7.1 Regeneron Pharmaceuticals, Inc. Details
2.7.2 Regeneron Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Regeneron Pharmaceuticals, Inc. SWOT Analysis
2.7.4 Regeneron Pharmaceuticals, Inc. Product and Services
2.7.5 Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.8 Xencor, Inc.
2.8.1 Xencor, Inc. Details
2.8.2 Xencor, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Xencor, Inc. SWOT Analysis
2.8.4 Xencor, Inc. Product and Services
2.8.5 Xencor, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.9 Glenmark Pharmaceuticals Limited
2.9.1 Glenmark Pharmaceuticals Limited Details
2.9.2 Glenmark Pharmaceuticals Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Glenmark Pharmaceuticals Limited SWOT Analysis
2.9.4 Glenmark Pharmaceuticals Limited Product and Services
2.9.5 Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.10 Ligand Pharmaceuticals, Inc.
2.10.1 Ligand Pharmaceuticals, Inc. Details
2.10.2 Ligand Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Ligand Pharmaceuticals, Inc. SWOT Analysis
2.10.4 Ligand Pharmaceuticals, Inc. Product and Services
2.10.5 Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.11 Fresenius
2.11.1 Fresenius Details
2.11.2 Fresenius Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Fresenius SWOT Analysis
2.11.4 Fresenius Product and Services
2.11.5 Fresenius Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
2.12 Merus
2.12.1 Merus Details
2.12.2 Merus Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Merus SWOT Analysis
2.12.4 Merus Product and Services
2.12.5 Merus Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Bi-Specific Antibodies Therapy Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Bi-Specific Antibodies Therapy Players Market Share
3.2.2 Top 10 Bi-Specific Antibodies Therapy Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Bi-Specific Antibodies Therapy Revenue and Market Share by Regions
4.2 North America Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
4.3 Europe Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
4.5 South America Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
5 North America Bi-Specific Antibodies Therapy Revenue by Countries
5.1 North America Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
5.2 USA Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
5.3 Canada Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
5.4 Mexico Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
6 Europe Bi-Specific Antibodies Therapy Revenue by Countries
6.1 Europe Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
6.2 Germany Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
6.3 UK Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
6.4 France Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
6.5 Russia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
6.6 Italy Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Countries
7.1 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
7.2 China Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
7.3 Japan Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
7.4 Korea Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
7.5 India Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
8 South America Bi-Specific Antibodies Therapy Revenue by Countries
8.1 South America Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
8.2 Brazil Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
8.3 Argentina Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Bi-Specific Antibodies Therapy by Countries
9.1 Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
9.2 Saudi Arabia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
9.3 UAE Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
9.4 Egypt Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
9.5 South Africa Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Bi-Specific Antibodies Therapy Revenue and Market Share by Type (2015-2020)
10.2 Global Bi-Specific Antibodies Therapy Market Forecast by Type (2019-2024)
10.3 Asymmetric Antibodies Revenue Growth Rate (2015-2025)
10.4 Symmetric Antibodies Revenue Growth Rate (2015-2025)
10.5 Fragment Antibodies Revenue Growth Rate (2015-2025)
11 Global Bi-Specific Antibodies Therapy Market Segment by Application
11.1 Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2015-2020)
11.2 Bi-Specific Antibodies Therapy Market Forecast by Application (2019-2024)
11.3 Colon Cancer Revenue Growth (2015-2020)
11.4 Prostate Cancer Revenue Growth (2015-2020)
11.5 Cervical Cancer Revenue Growth (2015-2020)
11.6 Breast Cancer Revenue Growth (2015-2020)
11.7 Lung Cancer Revenue Growth (2015-2020)
11.8 Others Revenue Growth (2015-2020)
12 Global Bi-Specific Antibodies Therapy Market Size Forecast (2021-2025)
12.1 Global Bi-Specific Antibodies Therapy Market Size Forecast (2021-2025)
12.2 Global Bi-Specific Antibodies Therapy Market Forecast by Regions (2021-2025)
12.3 North America Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
12.4 Europe Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
12.6 South America Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Bi-Specific Antibodies Therapy Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Bi-Specific Antibodies Therapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Bi-Specific Antibodies Therapy Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Bi-Specific Antibodies Therapy Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Bi-Specific Antibodies Therapy Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Amgen Inc. Corporate Information, Location and Competitors
Table 7. Amgen Inc. Bi-Specific Antibodies Therapy Major Business
Table 8. Amgen Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 9. Amgen Inc. SWOT Analysis
Table 10. Amgen Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 11. Amgen Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Aptevo Therapeutics Inc. Corporate Information, Location and Competitors
Table 13. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Major Business
Table 14. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2018-2019)
Table 15. Aptevo Therapeutics Inc. SWOT Analysis
Table 16. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 17. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. OncoMed Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 19. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Major Business
Table 20. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 21. OncoMed Pharmaceuticals, Inc. SWOT Analysis
Table 22. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 23. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Roche Corporate Information, Location and Competitors
Table 25. Roche Bi-Specific Antibodies Therapy Major Business
Table 26. Roche Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 27. Roche SWOT Analysis
Table 28. Roche Bi-Specific Antibodies Therapy Product and Solutions
Table 29. Roche Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. MacroGenics, Inc. Corporate Information, Location and Competitors
Table 31. MacroGenics, Inc. Bi-Specific Antibodies Therapy Major Business
Table 32. MacroGenics, Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 33. MacroGenics, Inc. SWOT Analysis
Table 34. MacroGenics, Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 35. MacroGenics, Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. AbbVie Inc. Corporate Information, Location and Competitors
Table 37. AbbVie Inc. Bi-Specific Antibodies Therapy Major Business
Table 38. AbbVie Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 39. AbbVie Inc. SWOT Analysis
Table 40. AbbVie Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 41. AbbVie Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Regeneron Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 43. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Major Business
Table 44. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 45. Regeneron Pharmaceuticals, Inc. SWOT Analysis
Table 46. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 47. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Xencor, Inc. Corporate Information, Location and Competitors
Table 49. Xencor, Inc. Bi-Specific Antibodies Therapy Major Business
Table 50. Xencor, Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 51. Xencor, Inc. SWOT Analysis
Table 52. Xencor, Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 53. Xencor, Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Glenmark Pharmaceuticals Limited Corporate Information, Location and Competitors
Table 55. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Major Business
Table 56. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 57. Glenmark Pharmaceuticals Limited SWOT Analysis
Table 58. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Product and Solutions
Table 59. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Ligand Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 61. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Major Business
Table 62. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 63. Ligand Pharmaceuticals, Inc. SWOT Analysis
Table 64. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product and Solutions
Table 65. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Fresenius Corporate Information, Location and Competitors
Table 67. Fresenius Bi-Specific Antibodies Therapy Major Business
Table 68. Fresenius Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 69. Fresenius SWOT Analysis
Table 70. Fresenius Bi-Specific Antibodies Therapy Product and Solutions
Table 71. Fresenius Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Merus Corporate Information, Location and Competitors
Table 73. Merus Bi-Specific Antibodies Therapy Major Business
Table 74. Merus Bi-Specific Antibodies Therapy Total Revenue (USD Million) (2017-2018)
Table 75. Merus SWOT Analysis
Table 76. Merus Bi-Specific Antibodies Therapy Product and Solutions
Table 77. Merus Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. Global Bi-Specific Antibodies Therapy Revenue (Million USD) by Players (2015-2020)
Table 79. Global Bi-Specific Antibodies Therapy Revenue Share by Players (2015-2020)
Table 80. Global Bi-Specific Antibodies Therapy Revenue (Million USD) by Regions (2015-2020)
Table 81. Global Bi-Specific Antibodies Therapy Revenue Market Share by Regions (2015-2020)
Table 82. North America Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
Table 83. North America Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Table 84. Europe Bi-Specific Antibodies Therapy Revenue (Million USD) by Countries (2015-2020)
Table 85. Asia-Pacific Bi-Specific Antibodies Therapy Revenue (Million USD) by Countries (2015-2020)
Table 86. South America Bi-Specific Antibodies Therapy Revenue by Countries (2015-2020)
Table 87. South America Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Table 88. Middle East and Africa Bi-Specific Antibodies Therapy Revenue (Million USD) by Countries (2015-2020)
Table 89. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Table 90. Global Bi-Specific Antibodies Therapy Revenue (Million USD) by Type (2015-2020)
Table 91. Global Bi-Specific Antibodies Therapy Revenue Share by Type (2015-2020)
Table 92. Global Bi-Specific Antibodies Therapy Revenue Forecast by Type (2021-2025)
Table 93. Global Bi-Specific Antibodies Therapy Revenue by Application (2015-2020)
Table 94. Global Bi-Specific Antibodies Therapy Revenue Share by Application (2015-2020)
Table 95. Global Bi-Specific Antibodies Therapy Revenue Forecast by Application (2021-2025)
Table 96. Global Bi-Specific Antibodies Therapy Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Bi-Specific Antibodies Therapy Picture
Figure 2. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type in 2019
Figure 3. Asymmetric Antibodies Picture
Figure 4. Symmetric Antibodies Picture
Figure 5. Fragment Antibodies Picture
Figure 6. Bi-Specific Antibodies Therapy Revenue Market Share by Application in 2019
Figure 7. Colon Cancer Picture
Figure 8. Prostate Cancer Picture
Figure 9. Cervical Cancer Picture
Figure 10. Breast Cancer Picture
Figure 11. Lung Cancer Picture
Figure 12. Others Picture
Figure 13. Global Bi-Specific Antibodies Therapy Revenue (USD Million) and Growth Rate (2015-2025)
Figure 14. North America Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Europe Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Asia-Pacific Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. South America Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Middle East and Africa Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Bi-Specific Antibodies Therapy Revenue Share by Players in 2019
Figure 21. Global Top 5 Players Bi-Specific Antibodies Therapy Revenue Market Share in 2019
Figure 22. Global Top 10 Players Bi-Specific Antibodies Therapy Revenue Market Share in 2019
Figure 23. Key Players Market Share Trend
Figure 24. Global Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 25. Global Bi-Specific Antibodies Therapy Revenue Market Share by Regions (2015-2020)
Figure 26. Global Bi-Specific Antibodies Therapy Revenue Market Share by Regions in 2018
Figure 27. North America Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 28. Europe Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 29. Asia-Pacific Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 30. South America Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 31. Middle East and Africa Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 32. North America Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Figure 33. North America Bi-Specific Antibodies Therapy Revenue Market Share by Countries in 2019
Figure 34. USA Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 35. Canada Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 36. Mexico Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 37. Europe Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Figure 38. Europe Bi-Specific Antibodies Therapy Revenue Market Share by Countries in 2019
Figure 39. Germany Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 40. UK Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 41. France Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 42. Russia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 43. Italy Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Figure 45. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Share by Countries in 2019
Figure 46. China Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 47. Japan Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 48. Korea Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 49. India Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 50. Southeast Asia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 51. South America Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Figure 52. South America Bi-Specific Antibodies Therapy Revenue Market Share by Countries in 2019
Figure 53. Brazil Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 54. Argentina Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 55. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Countries (2015-2020)
Figure 56. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Countries in 2019
Figure 57. Saudi Arabia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 58. UAE Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 59. Egypt Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 60. South Africa Bi-Specific Antibodies Therapy Revenue and Growth Rate (2015-2020)
Figure 61. Global Bi-Specific Antibodies Therapy Revenue Share by Type (2015-2020)
Figure 62. Global Bi-Specific Antibodies Therapy Revenue Share by Type in 2019
Figure 63. Global Bi-Specific Antibodies Therapy Market Share Forecast by Type (2021-2025)
Figure 64. Global Asymmetric Antibodies Revenue Growth Rate (2015-2020)
Figure 65. Global Symmetric Antibodies Revenue Growth Rate (2015-2020)
Figure 66. Global Fragment Antibodies Revenue Growth Rate (2015-2020)
Figure 67. Global Bi-Specific Antibodies Therapy Revenue Share by Application (2015-2020)
Figure 68. Global Bi-Specific Antibodies Therapy Revenue Share by Application in 2019
Figure 69. Global Bi-Specific Antibodies Therapy Market Share Forecast by Application (2021-2025)
Figure 70. Global Colon Cancer Revenue Growth Rate (2015-2020)
Figure 71. Global Prostate Cancer Revenue Growth Rate (2015-2020)
Figure 72. Global Cervical Cancer Revenue Growth Rate (2015-2020)
Figure 73. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 74. Global Lung Cancer Revenue Growth Rate (2015-2020)
Figure 75. Global Others Revenue Growth Rate (2015-2020)
Figure 76. Global Bi-Specific Antibodies Therapy Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 77. Global Bi-Specific Antibodies Therapy Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 78. Global Bi-Specific Antibodies Therapy Revenue Market Share Forecast by Regions (2021-2025)
Figure 79. North America Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
Figure 80. Europe Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
Figure 81. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
Figure 82. South America Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
Figure 83. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Forecast (2021-2025)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel
CD38モノクローナル抗体の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The CD38 Monoclonal Antibodies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiza…- 組換え治療用抗体・タンパク質の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Recombinant Therapeutic Antibodies and Proteins market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 118990 million by 2025, from USD 92080 million in…
- モノクローナル抗体の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Monoclonal Antibodies market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Monoclonal Antibodies m…
- 注射型標的療法の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Injectable Targeted Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiz…
- 特定用途向け集積回路（ASIC）の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Application-specific Integrated Circuit (ASIC) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. Th…